Initial estimates of the minimal clinically important difference for the Neuropathic Pain Symptom Inventory: a...

Area of Science:

• Pain Medicine
• Clinical Trials Methodology
• Psychometrics

Background:

• The Neuropathic Pain Symptom Inventory (NPSI) is crucial for assessing neuropathic pain (NP) in clinical trials.
• Establishing a Minimal Clinically Important Difference (MCID) for the NPSI is essential for score interpretability.
• Current research lacks established MCID values for the NPSI, hindering clinical and research applications.

Purpose of the Study:

• To systematically review and meta-analyze existing scientific literature to calculate an MCID for the NPSI.
• To provide a quantitative measure for clinically significant improvements in NP symptoms assessed by the NPSI.
• To enhance the interpretability of NPSI scores in the context of NP research and clinical practice.

Main Methods:

• A systematic review and meta-analysis of randomized controlled trials (RCTs) utilizing the NPSI.
• Application of four distributional approaches: meta-regression and simple aggregation using standard deviation (SD) of change and baseline scores.
• Quality assessment of included studies using the Cochrane tool for risk of bias.

Main Results:

• Analysis of 17 treatment arms from 12 selected trials.
• Estimated MCID values for the NPSI total score ranged from 6.21 to 7.95.
• Sensitivity analysis for control arms yielded MCID estimates between 8.04 and 8.71.

Conclusions:

• Preliminary MCID estimates for the NPSI have been established.
• Further research, including anchor-based and etiology-specific studies, is needed to refine these estimates.
• The findings support improved trial design and result interpretation in neuropathic pain research.